"Obtention and evaluation of inclusion complexes of furosemide with β-ciclodextrin and hidroxipropil-β-ciclodextrim: Effects on drug's dissolution properties";Obtenção avaliação de complexos de inclusão de furosemida com β-ciclodextrina e hidroxipropil-β-ciclodextrina: Efeitos sobre as propriedades de dissolução do fármaco

Latin American Journal of Pharmacy

Volumn 27, Issue 5, 2008, Pages 645-653

  Spricigo, Rodrigo ^a   Botelho, Kátia C A ^a   Consiglieri, Vladi O ^a   Serra, Cristina H R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Complexation; Cyclodextrins; Dissolution efficiency; Freeze drying; Furosemide

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; FUROSEMIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FREEZE DRYING; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; PH MEASUREMENT;

EID: 63249083891     PISSN: 03262383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Brown, C.K., H.P. Chokshi, B. Nickerson, R.A Reed, B.R. Rohrs & P.A. Shah (2004) Pharm. Technol. 28: 56-65.
2. Brewster, M.E. & T. Loftsson (2007) Adv. Drug Deliv. Rev. 59: 645-66.
3. Loftsson, T. & M.E. Brewster (1996) J. Pharm. Sci. 85: 1017-25.
4. Szejtli, J. (1988) "Cyclodextrin Technology", Kluwer Academic Publishers, Dordrecht, págs. 79-185.
5. Szejtli, J. & T, Osa (1996) "Chemistry physical and biological properties of cyclodextrins", Pergamon, Oxford, págs.5-40.
6. Szente, L. & J. Szejtli (1999) Adv. Drug Deliv. Rev. 36: 17-28.
7. Oates, J.A (1996) "Fármacos anti-hipertensivos e terapia farmacológica da hipertensão", en "Goodman & Gilman: As bases farmacológicas da terapêutica". (J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon & A.G. Gilman, ed) Editora Guanabara Koogan S.A., Rio de Janeiro, cap 29, págs. 501-22.
8. Murray, M.D., K.M. Haag, P.K. Black, S.D. Hall & D.C. Brater (1997) Pharmacother. 17: 98-106.
9. Sweetman, S.C., ed. (2006) "Martindale. The complete drug reference". Pharmaceutical Press, London (electronic version).
10. Ponto, L.L. & R.D. Schoenwald (1990) Clin. Pharmacokinet. 18: 381-408.
11. McCrindle J.L., T.C, Li Kam Wa, W. Barron & L.T. Prescott (1996) Br. J. Clin. Pharmacol. 42: 743-6.
12. Pitha, J., J. Mileçki, H. Fabs, L. Pannell & K. Eekama (1986) Int. J. Pharm. 29: 73-82.
13. Kata, M. & G. Kedvessy (1987) Pharm. Ind. 49: 98-100.
14. Kreaz, R.M.A., G.Y. Dombi & M. Kata (1998) J. Inclusion Phen. Macrocyclic Chem. 31: 189-96.
15. Ozdemir, N. & S. Ordu (1998) Drug. Dev. Ind. Pharm. 24: 19-25.
16. Ammar, H.O., M. Ghorab, S.A. El-nahhas, L.H. Emara & T.S. Makram (1999) Pharmazie 54: 142-4.
17. Spamer, E., D.G. Müller, P.L. Wessels & J.P. Venter (2002) Eur. J. Pharm. Sci. 16: 247-53.
18. Vlachou, M. & G. Papaioannou (2003) J. Biomat. Applications. 17: 197-206.
19. The United States Phamacopeia USP XXVIII (2005) United States Phamacopeia Convention Inc. Rockville, Maryland.
20. Khan, K.A. & C.T. Rhodes (1975) J. Pharm. Pharmacol. 27: 48-9.
21. Serra, C.H.R. & S. Storpirtis (2007) Braz. J. Pharm. Sci. 43: 79-88.
22. Pita, N.O.G., E.C. Prates & H.G. Ferraz (2004) Braz. J. Pharm. Sci. 40: 309-15.
23. Faria, A. N. (2002) Arq. Bras. Endocrinol. Metab. 46: 137-42.
24. Brater, D.C. (1983) Fed. Proc. 42: 1711-3.
25. Kantelip J.P., J.M. Aiache, E. Beyssac & M.I. Abella (1991) Therapie. 46: 475-9.
26. Kreaz, R.M.A., C. Novák, I. Erös & M. Kata (1999) J. Therm. Anal. Calor. 55: 122-5.
27. Özkan, Y., T. Atay, N. Dikmen, A. Ismer & H.Y. Aboul-Enein (2000) Pharm. Acta Helv. 74: 365-70.
28. O'hara, T., A. Dunne, J. Butler & J. Devane (1998) Pharm. Sci. Technol. 1: 214-23.